523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis

Van Nieuwenhuysen, E., O’Malley, D., O’Cearbhaill, R. E., Moore, K. N., Hamilton, E. P., Yeku, O., Bouberhan, S., Hou, J. Y., Yoo, S.-Y., Brouwer-Visser, J., Cheung, H. K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T. S., Miller, E. A., & Liu, J. F. (2022). 523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis. Annals of Oncology, 33, S784. https://doi.org/10.1016/j.annonc.2022.07.651
Authors:
Els Van Nieuwenhuysen
D. O'Malley
R.E. O'Cearbhaill
K.N. Moore
E.P. Hamilton
O. Yeku
S. Bouberhan
J.Y. Hou
S-Y. Yoo
J. Brouwer-Visser
H.K. Cheung
M. Peterman
P. Goncalves
T. Schmidt
M. Zhu
I. Lowy
T. Rowlands
T.S. Uldrick
E.A. Miller
J.F. Liu
Affiliated Authors:
J.Y. Hou
Columbia Affiliation:
Subjects:
Therapeutic Antibodies: Development, Engineering, and Applications (OpenAlex Topic)
Role of Galectins in Immunity and Disease (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2022.07.651
DOI:
10.1016/j.annonc.2022.07.651
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: